Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exenatide Once Weekly vs Twice Daily in Type 2 Diabetes (DURATION-NEO-1)
NCT01652716Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Jan 2013
- Primary completion
- Aug 2014
- Modality
- Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of exenatide in type 2 diabetes mellitus (T2DM), sponsored by AstraZeneca. Started Jan 2013; status: completed.
02
Drugs
exenatide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT01652716.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01652716.